Competition Commission has slapped a penalty of Rs 64 crore on drugmakers GlaxoSmithKline Pharmaceuticals and Sanofi for collusive bidding in supply of a meningitis vaccine to the government for Haj pilgrims.
The matter relates to supply of polysaccharide Quadrivalent Meningococcal Meningitis (QMMV) vaccines and the complaint was filed by Bio-Med Pvt Ltd, which also makes this drug. The complaint was also filed against the Health and Family Welfare Ministry.
Every year, the government invites tenders for purchase of meningitis vaccine that is required to be administered upon Haj pilgrims.
Full content: The Economic Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI